Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs

Liang Zhang, Zhongwei Zhang, Ralph P. Mason, Jann N. Sarkaria, Dawen Zhao

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


There is considerable interest in developing nanohybrids of imaging contrast agents and drugs for image-guided drug delivery. We have developed a strategy of utilizing manganese (Mn) to enhance the nano-encapsulation of arsenic trioxide (ATO). Formation of arsenite (As3+)-Mn precipitates in liposomes generates magnetic susceptibility effects, reflected as dark contrast on T2-weighted MRI. Intriguingly, following cell uptake, the As-Mn complex decomposes in response to low pH in endosome-lysosome releasing ionic As3+, the active form of ATO, and Mn2+, the T1 contrast agent that gives a bright signal. Glioblastoma (GBM) is well known for its high resistance to chemotherapy, e.g., temozolomide (TMZ). Building upon the previously established phosphatidylserine (PS)-targeted nanoplatform that has excellent GBM-targeting specificity, we now demonstrate the effectiveness of the targeted nanoformulated ATO for treating TMZ-resistant GBM cells and the ability of the convertible Mn contrast as a surrogate revealing the delivery and release of ATO.

Original languageEnglish (US)
Article number9874
JournalScientific reports
StatePublished - May 12 2015

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs'. Together they form a unique fingerprint.

Cite this